Back to Search
Start Over
Effect of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction: a meta‐analysis
- Source :
- ESC Heart Failure, Vol 11, Iss 3, Pp 1352-1376 (2024)
- Publication Year :
- 2024
- Publisher :
- Wiley, 2024.
-
Abstract
- Abstract Heart failure is the final stage of several cardiovascular diseases, and the key to effectively treating heart failure is to reverse or delay ventricular remodelling. Levosimendan is a novel inotropic and vasodilator agent used in heart failure, whereas the impact of levosimendan on ventricular remodelling is still unclear. This study aims to investigate the impact of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction. Electronic databases were searched to identify eligible studies. A total of 66 randomized controlled trials involving 7968 patients were included. Meta‐analysis results showed that levosimendan increased left ventricular ejection fraction [mean difference (MD) = 3.62, 95% confidence interval (CI) (2.88, 4.35), P
Details
- Language :
- English
- ISSN :
- 20555822
- Volume :
- 11
- Issue :
- 3
- Database :
- Directory of Open Access Journals
- Journal :
- ESC Heart Failure
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.1f92f313b6434f79b39e4e2ca7e8eb07
- Document Type :
- article
- Full Text :
- https://doi.org/10.1002/ehf2.14714